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Available online 1 March 2012Human Transforming Growth Factor (TGF)-β1, one of three TGF-β isoforms, is a pleotropic
cytokine critical for many physiological and immunological processes. TGF-β1 is secreted in
a latent form, linked to Latency Associated Protein (LAP). Analysis of Latent TGF-β1 by TGF-
β1 ELISA requires dissociation of TGF-β1 from LAP, e.g. by acidification of samples. The ELISA
then measures total TGF-β1, equivalent to dissociated Latent TGF-β1 plus any free TGF-β1 pre-
sent prior to acidification. Evolutionary conservation of TGF-β1 across mammals also renders
TGF-β1 ELISAs reactive with TGF-β1 in bovine serum often used in human cell cultures. To
enable a direct analysis of Latent TGF-β1, monoclonal antibodies were made against LAP
from human Latent TGF-β1 and used to develop a LAP ELISA detecting Latent TGF-β1. The
ELISA did not react with LAP from human Latent TGF-β2 or 3, respectively, nor with Latent
TGF-β in bovine serum. EDTA-containing plasma from healthy subjects (n=20) was analyzed
by conventional TGF-β1 ELISA and LAP ELISA. By TGF-β1 ELISA, total TGF-β1 were detected in
all samples (median 133 pM, range 34–348 pM); low levels of free TGF-β1 found in 8/20 non-
acidified samples showed that >98.5% of the total TGF-β1 derived from Latent TGF-β1. Latent
TGF-β1 found in non-acidified samples by LAP ELISA (median 154 pM, range 48–403 pM) was
comparable in molar levels to, and correlated with, total TGF-β1 (rs 0.96, pb0.0001). A similar
agreement between the total TGF-β1 and the LAP ELISA was found with citrate- and heparin-
containing plasma. The LAP ELISA facilitates analysis of Latent TGF-β1 without sample acidifica-
tion and is not compromised by the presence of bovine serum in human cell supernatants.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. Keywords:
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Total TGF-β11. Introduction
Transforming Growth Factor-(TGF)-β1 is involved in a
multitude of physiological processes including regulation of
cell proliferation and differentiation, developments in the ex-
tracellular matrix and wound healing (Li et al., 2006). Bone
matrix and platelets are primary sources of TGF-β1 but it isn fluorescent protein;
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hlborg).
Y-NC-ND license. produced by many other cells (Govinden and Bhoola, 2003).
TGF-β1 also plays an important role as a modulator of the im-
mune system and is one of the hallmarks of CD4+ CD25+
regulatory T cells that primarily display suppressive effects
(Wahl et al., 2006).
Humans and other mammals have three isoforms of TGF-β
that are translated as pro-proteins linked to a Latency Associat-
ed Protein (LAP) which is unique for each isoform. TGF-β iso-
forms are proteolytically cleaved from LAP but the two
proteins remain together and are secreted in a latent complex
(Latent TGF-β) comprising a dimer of TGF-β non-covalently as-
sociated with a dimer of LAP (Fig. 1) (Koli et al., 2001;
Lawrence, 2001). Yet another family of proteins, Latent TGF-β
Binding Protein (LTBP)-1, −3 and −4, can bind to LAP and
form a large Latent TGF-β complex which increases the
Signal LAP TGF- 1
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Fig. 1. Translation and secretion of Latent TGF-β1. TGF-β1 is translated as a
pre-proprotein with LAP preceding TGF-β1. The signal peptide is removed
when the proprotein enters the secretory pathway and forms a dimer. Before
secretion, the protein is proteolytically cleaved between LAP and TGF-β1 but
the twoproteins remain together as a small Latent TGF-β1 complex comprising
a disulfide-linked LAP dimer non-covalently linked to a disulfide-linked dimer
of TGF-β1. In addition, LTBP can form a disulfide link to LAP to form a large
Latent TGF-β1 complex (not shown). The Latent TGF-β1 complex has to disso-
ciate extracellularly before TGF-β1 binds its receptor.
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matrix (Saharinen et al., 1999; Saharinen and Keski-Oja, 2000).
Extracellular activation of Latent TGF-β resulting in the release
of LAP is required for TGF-β binding to its receptor. Mecha-
nisms involved in TGF-β activation under physiological condi-
tions most likely involve enzymatic as well as pH-dependent
processes (Lawrence, 2001).
Given its importance, human TGF-β1 is measured in serum
and plasma to investigate its potential dysregulation in various
diseases (Hellmich et al., 2000; Juraskova et al., 2010;
Lawrence, 2001; Malaguarnera et al., 2002; Mieliauskaite et
al., 2009; Szkaradkiewicz et al., 2010; Yang et al., 1999) and
in cell supernatants for research on physiological or immuno-
logical processes (Kropf et al., 1997; Jurukovski et al., 2005).
Since TGF-β1 is secreted in a latent form and primarily is
found as such, analysis of the latent formby TGF-β1 ELISA com-
monly includes acidification of samples to dissociate TGF-β1
from LAP, a prerequisite for the recognition by the ELISA. Anal-
ysis is made immediately after neutralization of the acidified
sample as TGF-β1 and LAP1 (from here on LAP from Latent
TGF-β1, 2 and 3 is termed LAP1, 2 and 3, respectively) other-
wise can re-associate (Kropf et al., 1997). The total TGF-β1
measured corresponds to TGF-β1 dissociated from its latent
form plus any free bioactive TGF-β1 potentially present in
the samples prior to the dissociation; the level of bioactive
TGF-β1 generally represents a minor fraction of the total TGF-
β1 (Hellmich et al., 2000; Walther et al., 2009).Evolutionary conservation of TGF-β1 in mammals adds to
the complexity when cell supernatants are analyzed. The
common use of fetal bovine serum (FBS) in human cell cul-
tures is an issue since FBS contains significant levels of Latent
TGF-β1 and human TGF-β1 ELISA systems inevitably cross-
react with bovine TGF-β1.
Because of the issues involved in the analysis of Latent
TGF-β1 by TGF-β1 ELISA, an assay allowing a more straight-
forward measurement of Latent TGF-β1 was developed.
Monoclonal antibodies (mAb) were made against human
LAP1 and an ELISA reactive with Latent TGF-β1 was devel-
oped. The LAP ELISA measured Latent TGF-β1 without pre-
ceding acidification of human samples and did not cross-
react with LAP2 or −3. No cross-reactivity of the LAP ELISA
with Latent TGF-β in bovine serum was found making the
ELISA suitable also for human cell supernatants containing
bovine serum.
2. Materials and methods
2.1. Production of mAbs against LAP1
BALB/c mice were immunized subcutaneously with 10 μg
recombinant human (rh) Latent TGF-β1 (R&D Systems,
Abingdon, UK) in 50 μl phosphate-buffered saline (PBS) and
50 μl Freund's complete adjuvant (Sigma-Aldrich, St. Louis,
MO, USA). Mice were boosted using Freund's incomplete ad-
juvant week 4 and 7 (Sigma). At week 27, 10 μg antigen in
PBS was given intraperitoneally and 3 days later spleen cells
were fused with Sp2/0 cells as described (elGhazali et al.,
1993). Positive hybridomas identified by indirect ELISA
were subcloned and cultured. MAbs were purified and bioti-
nylated as described (Zuber et al., 2005). Mice were housed
and handled at the Karolinska Institute, Solna, Sweden,
according to the guidelines of the Swedish Ethical Committee
for Animal Protection.
2.2. Indirect ELISA for analysis of antibody speciﬁcity
Maxisorp 96-well plates (Nunc, Roskilde, Denmark) were
coated for 16 h at 4 °C with 2 μg/ml of rh LAP1, Latent TGF-β1
or TGF-β1 (R&D Systems) in 100 μl PBS. Other assay steps
were at room temperature (RT), using 100 μl/well. Five washes
using PBS with 0.1% Tween 20weremade between assay steps.
After coating, wells were blocked for 1 h with incubation buffer
(PBS with 0.05% Tween 20 and 0.1% bovine serum albumin).
Hybridoma supernatants were diluted in incubation buffer
and incubated 2 h.Next, goat-anti-mouse IgG alkalinephospha-
tase conjugate (Mabtech, Nacka Strand, Sweden) was added
and incubated for 1 h, followed by development with para-
nitrophenyl phosphate (Sigma) and absorbance measurement
(405 nm) by an ELISA reader (Labsystems, Helsinki, Finland).
2.3. Capture ELISA
In the LAP ELISA, mAb MT593 (IgG1) was coated at 2 μg/ml
and wells were blocked as above. Volumes and temperature
for all assay steps and washes in between were as above.
Human plasma was diluted in an ELISA diluent (Mabtech) pre-
venting potential interference by heterophilic antibodies in the
samples (Bolstad et al., 2011). Also rh LAP1, Latent TGF-β1 and
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diluent was added to acidified samples after the acid treatment.
After sample incubation for 2 h, mAb MT517-biotin (IgG1) at
1 μg/ml in ELISA diluent was incubated 1 h followed by
streptavidin-horse radish peroxidase conjugate (SA-HRP;
Mabtech) in incubation buffer for 1 h. The assay was developed
with 3,3′,5,5′-tetramethylbenzidine substrate (Mabtech) and
stopped with 1 M H2SO4 followed by absorbance measurement
(450 nm). The same protocol was used for TGF-β1 ELISA
(Human TGF-β1 DuoSet kit specific for TGF-β1; R&D Systems).
Sample levels were determined against standards using
rhLAP1 in the LAP ELISA and rhTGF-β1 in the TGF-β1 ELISA.
Molar levels are used to be able to compare TGF-β1 (26 kD)
and Latent TGF-β1 (80 kD) and because the Mw of the rhLAP1
standard (54 kD) differs from that of Latent TGF-β1 in non-
acidified samples.
2.4. Plasmid, genes and transfection
Protein sequences for LAP from human Latent TGF-β1
(P01137, aa 1–278), -β2 (P61812, aa 1–302) and −β3
(P10600, aa 1–300) were from UniProt (www.uniprot.org).
The corresponding genes were synthesized including a se-
quence encoding a C-terminal His6 tag and cloned into a
pIRES2-AcGFP1 plasmid (Clontech, Mountain View, CA,
USA) using the restriction enzymes XhOI and BamHI; plas-
mids were verified by sequencing (made by GenScript,
Piscataway, NJ, USA) CHO-K1 cells (ATCC, Teddington, UK)
cultured in F-12 K Kaighn's medium with 10% FBS, penicillin
(100 U/ml) and streptomycin (100 μg/ml) (Gibco/Invitrogen,
Grand Island, NY, USA) were transfected with LAP or mock
plasmids using lipofectamine 2000 (Gibco). Briefly, CHO-K1
cells were seeded at 1.2×105 cells/well in a 24-well cell-
culture plate (Corning, Lowell, MA, USA). The following day,
0.8 μg plasmid was incubated with 3 μl lipofectamine 2000
in OPTI-MEM I reduced serum medium (Gibco) for 20 min
and gently added to the cells. Transfected cells were incubated
at 37 °C in 5% CO2.
2.5. Analysis of transfected CHO-K1 cells
Cell supernatants were harvested 24 h after transfection and
cells were washed with PBS. Cell lysates weremade by incubat-
ing cells in PBS with 0.5% Triton-X 100 at RT for 5 min followed
by centrifugation at 800×g (10 min). Cell and lysate superna-
tants were analyzed by LAP ELISA. Transfected cells were also
analyzed by ELISpot as described (Zuber et al., 2005) utilizing
the LAP ELISA mAbs. For flow cytometry, cells were incubated
in fixation-permeabilization buffer (Becton Dickinson, Franklin
Lakes, NJ, USA) for 20 min at 4 °C. Permeabilization-wash buffer
(Becton Dickinson) was used for washing and the cells were
incubated 30 min at 4 °C with anti-His6 mAb ab72467-
phycoerythrin (Abcam, Cambridge, MA, USA), at 2 μg/ml in the
same buffer. Cells were again washed, re-suspended in PBS
with 1% FBS and 0.09% sodium azide and acquired in a Guava
EasyCyte Mini flow cytometer (Millipore, Billerica, MA, USA).
Data was analyzed using the FlowJo software (FlowJo, Ashland,
OR, USA). LAP1 was purified from cell supernatant on a nickel
column (GE Healthcare, Uppsala, Sweden) and on mAb MT593
coupled to Amino Link® (Thermo Scientific, Rockford, IL, USA)
according to the manufacturers' instruction. Purified LAP1 wasanalyzed by SDS-PAGE and Western blot (Zuber et al., 2005).
For Western blot, all mAbs obtained were evaluated but only
mAbMT324 (IgG1) recognized LAP1 in a denatured state. To as-
sess individual mAb reactivity with transfected CHO cell super-
natant and lysate, an alternative capture ELISA assay was used.
Wells coated with anti-His6 mAb (GenScript) were incubated
with LAP1, -2 and−3 CHO cell samples, followed by detection
with biotinylated anti-LAP1mAbs and SA-HRP. Other assay con-
ditions were as in the capture ELISA described above.
2.6. Preparation of samples for TGF-β1 and LAP ELISA
Plasma from healthy subjects (n=20) was prepared from
venous blood obtained in EDTA Vacutainer vials (Becton
Dickinson) by centrifugation at 1000×g (10 min) followed by
an additional centrifugation of collected plasma at 10,000×g
(10 min) to obtain low platelet plasma. Blood was obtained
with informed consent. From six subjects, plasmawas also pre-
pared from blood in heparin or citrate vials (Becton Dickinson)
and peripheral bloodmononuclear cells (PBMC)were obtained
by Ficoll separation of heparinized blood samples. PBMC
(3×106 cells/ml) supernatants were collected after 2 days cul-
ture in AIM-V serum free medium (Gibco) at 37 °C in 5% CO2.
Animal samples used were rhesus and cynomolgus macaque
plasma (from the Swedish Center for Disease Control, Solna
Sweden), and serum from cow and horse (Gibco), mouse and
rat (Sigma) and goat (Jackson ImmunoResearch, Suffolk, UK).
All samples were stored at−20 °C until tested. For analysis in
ELISA, samples were used as such or were treated with 1 M
HCl (50 μl acid/100 μl plasma or serum; 20 μl acid/100 μl
PBMC supernatant) at RT for 10 min followed by addition of
1 M NaOH with 0.5 M Hepes (50 μl for plasma or serum; 20 μl
for PBMC supernatant).
2.7. Statistics
The relationship between observed levels of analytes in
the LAP and TGF-β1 ELISA was evaluated by Spearman rank
correlation (Analyse-it Software Ltd., Leeds, UK).
3. Results
3.1. Development of a mAb-based LAP ELISA reactive with
human Latent TGF-β1
Twenty mAbs obtained frommice immunized with Latent
TGF-β1 all reacted with LAP1 and Latent TGF-β1 but not TGF-
β1 in indirect ELISA. Combinations of all mAbs were evaluat-
ed in capture ELISA. MAb MT593 together with MT517-biotin
yielded the best detection of LAP1 and Latent TGF-β1 with no
reactivity with TGF-β1 (Fig. 2A). A TGF-β1 ELISA used in par-
allel displayed the opposite reactivity pattern recognizing
only TGF-β1 (Fig. 2B).
3.2. Speciﬁcity analysis of LAP ELISA with LAP from human
Latent TGF-β1, -2 and −3
CHO-K1 cells were transfected with plasmids encoding
LAP isoforms and a GFP reporter. In flow cytometry, all plas-
mids yielded GFP+transfected cells. Expression of LAP was
confirmed using a mAb to the C-terminal His6-tag in all LAP
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Fig. 2. Specificity of LAP and TGF-β1 ELISA. Serial dilutions of rh LAP1, Latent
TGF-β1 and TGF-β1 were analyzed by LAP (A) and TGF-β1 (B) ELISA. The
molar concentration of proteins is given on the X axis and the absorbance
on the Y axis. The lowest detection limit (3 times the mean background in
three experiments) in the LAP ELISA using rhLAP1 as standard was
0.24 pM (equal to 13 pg/ml). The corresponding value for the TGF-β1
ELISA using rhTGF-β1 standard was 0.12 pM (equal to 3.1 pg/ml).
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Fig. 3. Specificity of LAP ELISA for human LAP isoforms. CHO-K1 cells were
transfected with plasmids encoding LAP1, -2 and −3 (from Latent TGF-β1,
-2 and −3, respectively) including a C-terminal His6-tag followed by a GFP
reporter. A) By flow cytometry, successful transfection was verified by mea-
suring GFP+cells and expression of LAP was assessed with a phycoerythrin-
labeled mAb to the His6 tag. On the Y-axis, the frequency of GFP+His6+
cells is shown. Mock transfectants exposed to a plasmid encoding only GFP
were included as a negative control. B) LAP1 was affinity purified from
supernatant of LAP1-transfected cells on mAb MT593 and analyzed by
SDS-PAGE. LAP1 was also purified on a nickel column and analyzed by
mAb MT324 in Western blot. The presence of homodimers was verified by
dithiothreitol (DTT) reduction to monomers. C and D) Serial dilutions of
cell supernatants (C) and cell lysates (D) from CHO cells transfected as
above were analyzed by LAP ELISA. The reciprocal dilution of samples is
given on the X axis and the absorbance on the Y axis.
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8 to 16% with a background b1% in mock transfectants
(Fig. 3A). A similar frequency of LAP1+ transfected cells
was found in ELISpot, utilizing the LAP ELISA mAbs, whereas
the other transfectants were negative (data not shown). Puri-
fied LAP1 migrated as an 80 kD homodimer in SDS-PAGE
and could be reduced to monomers (Fig. 3B). An additional
LAP-reactive mAb obtained, MT324, yielded similar results
in Western blot (Fig. 3B). Analysis of cell supernatants
(Fig. 3C) and lysates (Fig. 3D) from LAP1, -2, −3 and mock
transfectants in the LAP ELISA confirmed a specificity restricted
to LAP1.
Also the individual reactivity of the LAP ELISA mAbs and
mAb MT324, the only mAb functional in Western blot, with
LAP1, -2 and −3 CHO cell supernatants was analyzed. All
three mAbs were specific for LAP1 with MT517 displaying
the strongest, and MT324 the weakest, reactivity (Fig. 4).
Similar data were obtained with CHO cell lysates (data not
shown).Reciprocal dilution
0 Mock
101 102 104103100 105
Fig. 4. Individual mAb reactivity with LAP isoforms analyzed by ELISA. Super-
natant from CHO cells transfected with plasmids encoding LAP1, -2 and −3
linked to a C-terminal His6-tag were incubated in wells coated with anti-His6
mAb and subsequently detected with biotinylated mAbs to LAP1 (MT517,
MT593 and MT324) or a control mAb to human IFN-γ. Included in the analysis
was supernatant frommock-transfected cells. The reciprocal dilution of super-
natant samples is given on the X axis and the absorbance on the Y axis.3.3. Measurement of Latent TGF-β1 in human plasma
Human EDTA-containing plasma (n=20) was analyzed
to assess if the LAP ELISA detection of Latent TGF-β1 was
comparable to a conventional total TGF-β1 analysis by TGF-
β1 ELISA.
The LAP ELISA yielded median levels of 154 pM (range
48–403 pM) in samples not treated with acid (Fig. 5A).Corresponding levels were found in acidified samples
(rs 0.97, pb0.0001; Fig. 5A). The LAP ELISA is thus neither de-
pendent nor affected by dissociation of Latent TGF-β1 for its
recognition.
As expected, the TGF-β1 ELISA required acid treatment for
detection in all samples (median 133 pM, range 35–350 pM;
Fig. 5B). Low levels of free TGF-β1 were detected in 8/10 non-
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>140 pM; the free TGF-β1 corresponded to 0–1.5% of the
total TGF-β1 levels. Samples with total TGF-β1 levels
b140 pM (n=10) were devoid of detectable free TGF-β1. It
can thus be estimated that >98.5% of the total TGF-β1 in
these samples was derived from dissociated Latent TGF-β1.
The molar levels of Latent TGF-β1 determined in samples
without acid treatment by the LAP ELISA and with acid treat-
ment by the TGF-β1 ELISA, were similar in magnitude and
correlated (rs 0.96, pb0.0001; Fig. 5C). A similar correlation
was found when comparing LAP and TGF-β1 ELISA results
using acid-treated samples in both ELISAs (data not shown).
3.4. Reactivity of LAP and TGF-β1 ELISA with different human
and animal samples
To assess the comparability of the two ELISAs with differ-
ent types of samples, samples from six subjects wereprepared by different means. In addition to EDTA, citrate
and heparin vials were used for plasma preparations and su-
pernatants from PBMC cultured in serum-free medium were
collected. Analysis of non-acidified samples by LAP ELISA
and acidified samples by TGF-β1 ELISA yielded comparable
results (Fig. 6A). However, the anti-coagulant used had an
impact on the levels with e.g. lower levels found in citrate
plasma.
The impact of having FBS present in cell supernatants was
tested by adding 25% FBS to three PBMC supernatants (data
not shown). Addition of FBS followed by acid treatment in-
creased the levels detected by TGF-β1 ELISA on average by
127 pM, close to the 120 pM of TGF-β1 found in 25% FBS
alone. Insignificant changes were seen in the LAP ELISA, irre-
spective of whether acid treatment was performed or not.
To further define the specificity of the LAP ELISA, plasma
and serum samples from various mammals were analyzed
(Fig. 6B). The LAP ELISA displayed reactivity with non-
acidified samples from rhesus and cynomolgus macaques but
not evolutionary more distant animals including cow, horse,
goat, rat and mouse. As expected, the TGF-β1 ELISA detected
TGF-β1 in all samples after acid treatment. Analysis of multiple
macaque and human plasmas (n=10 per species) demon-
strated that the LAP and TGF-β1 ELISA yielded comparable de-
tection not only in human samples but also in macaques.
4. Discussion
Analysis of human Latent TGF-β1 by TGF-β1 ELISA re-
quires dissociation of the latent complex, e.g. by acidification
28 I. Areström et al. / Journal of Immunological Methods 379 (2012) 23–29of samples. Amore straightforward ELISA based onmAbs to the
LAP entity was therefore developed. When the LAP ELISA was
used to measure Latent TGF-β1 in non-dissociated samples,
the observed levels were comparable to total TGF-β1 levels de-
termined by TGF-β1 ELISA. The correlation between the assays,
together with the fact that total TGF-β1 levels to >98.5% de-
rived from Latent TGF-β1, demonstrated the ability of the LAP
ELISA to measure Latent TGF-β1 in human samples.
Compared to the conventional analysis by TGF-β1 ELISA,
the LAP ELISA provides several advantages. The LAP ELISA
analysis can be made without preceding sample acidification
and neutralization, procedures that are necessary for the total
TGF-β1 ELISA but also involve an increased risk of errors
due to incomplete dissociation after acidification or re-
association after neutralization (Kropf et al., 1997). In the
LAP ELISA, acid treatment did not affect the levels deter-
mined demonstrating an equal reactivity of Latent TGF-β1
and dissociated LAP. In addition to simplifying the analytical
procedure, eliminating the use of acid facilitates inclusion of
LAP-specific reagents in multiplex analyses including cyto-
kines sensitive to low pH.
Each TGF-β isoform is preserved through evolution with
close to 100% homology across mammals. Human TGF-β1 is
e.g. identical to bovine TGF-β1 and differs only by one
amino acid from murine TGF-β1. TGF-β1 ELISAs therefore
react with TGF-β1 from bovine Latent TGF-β1, if bovine
serum has been added to human cell cultures. The LAP pro-
teins are less conserved and human LAP1 displays 92% and
85% homology to bovine and murine LAP1, respectively. Ac-
cordingly, no reactivity with bovine Latent TGF-β1 was dis-
played by the LAP ELISA, making it possible to analyze
human cell supernatants without interference by bovine
Latent TGF-β1. The LAP ELISA did however react with Latent
TGF-β1 from the evolutionary more closely related ma-
caques. The similar levels detected by LAP and TGF-β1
ELISA in macaques samples indicate a high degree of cross-
reactivity of the LAP ELISA which could be valuable consider-
ing the use of macaques as an animal model for various
human diseases including AIDS.
Compared to the high interspecies conservation of TGF-
β1, the homology between human TGF-β isoforms is lower
(≤77%) and even lower is the homology between LAP iso-
forms (≤41%). Consequently, the LAP ELISA did not recognize
LAP from human Latent TGF-β2 and −3. Also the individual
reactivity of the mAbs used in LAP ELISA as well as MT324,
the only mAb functional in Western blotting, was restricted
to LAP1.
A factor that could interfere with the detection of Latent
TGF-β1 by LAP ELISA is the binding of LTBPs to LAP. The cys-
teine residue at position 33 in LAP can form a disulfide bond
with LTBP and non-malignant cells generally secrete Latent
TGF-β1 as a large latent complex associated with LTBPs
(Mangasser-Stephan and Gressner, 1999). However, the
agreement between the LAP ELISA and the total TGF-β1
ELISA speaks against any such interference.
Measurement of Latent TGF-β1 could theoretically be
achieved using amAb to LAP and amAb to TGF-β1. However, al-
though a panel of mAbs was obtained from the Latent TGF-β1-
immunized mice herein, all mAbs recognized the LAP entity.
This implies that TGF-β1, in the latent complex, is poorly acces-
sible for antibodies. A limited accessibility of TGF-β1 in its latentform was also indicated by the finding that the mAbs to LAP
could not be combined with any of various commercially avail-
able antibodies to TGF-β1, to create a functional ELISA for Latent
TGF-β1 (unpublished data). A limited availability of TGF-β1 is
obviously also the reason forwhy Latent TGF-β1needs to be dis-
sociated in order to measure total TGF-β1.
The total TGF-β1 plasma levels measured by TGF-β1 ELISA
herein, were in accordance with expected levels. The average
total TGF-β1 levels in plasma from healthy control cohorts dif-
fers between studies but is generally between 40 and 800 pM
(approximately 1–20 ng/ml) although both higher and lower
levels are reported (Kropf et al., 1997; Sundman et al., 2011).
The rather large variation of total TGF-β1 levels found in differ-
ent studies using plasma from control subjects can to a large
extent be ascribed to the method used for sample preparation,
known to have a great impact on the resulting levels of total
TGF-β1 (Walther et al., 2009). In studies aiming to quantify
TGF-β1 levels in the blood, measures are often taken to elimi-
nate platelets as they otherwise can release high levels of
Latent TGF-β1 during sample preparation (Walther et al.,
2009). For this reason, plasma is preferred over serum but
many studies nevertheless use serum samples with high levels
of total TGF-β1 measured as a result. In this respect there is no
difference betweenmeasuring total TGF-β1 by TGF-β1 ELISA or
Latent TGF-β1 by LAP ELISA; samples prepared such that it re-
sults in platelet activation will yield high levels irrespective of
the method used for analysis. The choice of anti-coagulants
used to obtain plasma has been reported to have an impact
on the total TGF-β1 level as well (Walther et al., 2009). This
was also indicated by the finding herein that lower levels of la-
tent TGF-β1 was detected in citrate plasma samples compared
to heparin and EDTA plasma.
Also the plasma levels of free TGF-β1 vary between stud-
ies but are in general substantially lower than the total TGF-
β1 levels, if detectable at all (Hellmich et al., 2000; Walther
et al., 2009). In the plasma analyzed herein, free TGF-β1 cor-
responding to 0–1.5% of the total TGF-β1 was found. Culture
supernatants of human monocytes and other cell types have
also been reported to primarily contain Latent TGF-β1 and
little free TGF-β1 (Flaumenhaft et al., 1993; Lawrence,
2001; Twardzik et al., 1990).
Although the LAP ELISA facilitates an easier way of estimat-
ing Latent TGF-β1, it does not replace the use of TGF-β1 ELISA
formeasurement of free TGF-β1. In samples potentially contain-
ing unusually high levels of free TGF-β1, the two ELISA assays
can be used in parallel to measure latent versus free TGF-β1, re-
spectively. Such an analysis can be made without any need of
acid treatment and neutralization, and the potential errors asso-
ciated with those procedures. In addition to simplifying the
measurement of Latent TGF-β1, the LAP ELISA also enablesmea-
surement of human Latent TGF-β1 without interference in cell
culture supernatants containing bovine serum.
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